OQSIL BIOSINTEZI INGIBITORLARI: DORI VOSITALARI VA BAKTERIAL TOKSINLAR

Authors

  • Maxmudova Iroda Maruf qizi Farmatsiya, menejment, fundamental tibbiyot va oliy ma'lumotli hamshira fakulteti Fundamental tibbiyot yo'nalishi 2-kurs talabalari, TDTU, Toshkent, O'zbekiston, izlanuvchilar, irodamakhmudova1308@gmail.com, https://orcid.org/0009-0002-3877-1268 Author
  • Solijonova Gulchiroy Akmal qizi solijonova2025@icloud.com, https://orcid.org/0009-0009-4516-8687 Author
  • Abduraimova Zarbonu Sadriddin qizi abduraimovazarbonu08@gmail.com, https://orcid.org/0009-0008-5596-6546 Author
  • Nazirova Dilfuzaxon Narimonjon qizi nazirovadilfuzaxon0@gmail.com, https://orcid.org/0009-0008-1646-9571 Author
  • Odilova Shaxnoza Xayrulloyevna Toshkent davlat tibbiyot universiteti, Tibbiy va biologik kimyo kafedrasi assistenti shaxnoza.odilova.so83@gmail.com, https://orcid.org/0009-0004-3246-136X Author

Keywords:

oqsil biosintezi, ribosoma, antibiotiklar, bakterial toksinlar, PrAMP, 50S subbirlik, 30S subbirlik, antimikrob qarshilik

Abstract

Ushbu maqolada oqsil biosintezi ingibitorlarining ta’sir mexanizmlari, dori vositalari sifatidagi roli va bakterial toksinlar bilan aloqadorligi yoritilgan. Ribosoma oqsil sintezining markaziy organoidi bo‘lib, ko‘plab antibiotiklar va toksinlar uchun nishon sanaladi. Zamonaviy ilmiy adabiyotlar tahlili 50S va 30S ribosomal subbirliklarga ta’sir etuvchi makrolidlar, tetratsiklinlar, aminoglikozidlar, shuningdek, prolinga boy antimikrob peptidlar (PrAMP) kabi noyob tabiiy birikmalar mavjudligini ko‘rsatadi. Maqolada O‘zbekiston olimlari tomonidan olib borilgan tadqiqotlar, xalqaro ilmiy nashrlar va ishonchli veb-manbalar asosida ushbu ingibitorlarning molekulyar mexanizmlari va klinik ahamiyati muhokama qilinadi.

References

[1] Qodirov, A. M., & To‘raqulov, Y. H. (2021). Tibbiyot mikrobiologiyasi: antibiotiklar va ularning ta’sir mexanizmlari. Toshkent: Tibbiyot nashriyoti, 215-230.

[2] Ismoilov, R. F., Murodova, S. A. (2022). “Mahalliy shtammlarda tetratsiklin qarshilik genlarining molekulyar tahlili”. O‘zbekiston Biologiya jurnali, 3(71), 45-49.

[3] Yo‘ldoshev, N. M. (2020). “Ribosoma strukturasi va biosintez bosqichlari”. O‘zbekiston tibbiyot jurnali, 5(89), 112-118.

[4] Karimova, D. S., Rashidov, B. T. (2023). “Antimikrob peptidlarni biosintez qilishning zamonaviy usullari”. Biotexnologiya muammolari va rivoji, 1(28), 18-25.

[5] Sattarova, G. R. (2021). “Klinik amaliyotda oqsil sintezi ingibitorlariga rezistentlik darajasi”. Infeksion kasalliklar byulleteni, 4(56), 34-41.

[6] Abdullayev, Sh. Z., Zokirova, L. O. (2022). “O‘simlik ekstraktlarining ribosomal ingibitorlik faolligi”. Farmakologiya va fitoterapiya jurnali, 2(12), 77-84.

[7] Mardirossian, M., & Scocchi, M. (2020). “Proline-rich antimicrobial peptides: a new class of ribosome-targeting antibiotics”. Frontiers in Microbiology, 11, 1077.

[8] Wilson, D. N. (2014). “Ribosome-targeting antibiotics and mechanisms of bacterial resistance”. Nature Reviews Microbiology, 12(1), 35-48.

[9] Graf, M., Wilson, D. N. (2022). “The mechanism of action of proline-rich antimicrobial peptides”. Science Advances, 8(44), eabp8080.

[10] Lin, J., Zhou, D., Steitz, T. A., Polikanov, Y. S., Gagnon, M. G. (2018). “Ribosome-targeting antibiotics: modes of action, mechanisms of resistance, and implications for drug design”. Annual Review of Biochemistry, 87, 451-478.

[11] Ogura, T., & Tomoyasu, T. (2020). “Colicin E3 and its nuclease activity on ribosomal RNA”. Molecular Microbiology, 115(3), 435-445.

[12] Dinos, G. P. (2017). “The macrolide antibiotic renaissance”. British Journal of Pharmacology, 174(18), 2967-2983.

[13] Poehlsgaard, J., & Douthwaite, S. (2005). “The bacterial ribosome as a target for antibiotics”. Nature Reviews Microbiology, 3(11), 870-881.

[14] Harms, A., Brodersen, D. E., Mitarai, N., Gerdes, K. (2018). “Toxins, Targets, and Triggers: An Overview of Toxin-Antitoxin Biology”. Molecular Cell, 70(5), 768-784.

[15] Page, R., & Peti, W. (2016). “Toxin-antitoxin systems in bacterial growth arrest and persistence”. Nature Chemical Biology, 12(4), 208-214.

[16] Orelle, C., Carlson, S., Kaushal, B., Almutairi, M. M., Liu, H., Ochabowicz, A., ... & Mankin, A. S. (2013). “Tools for characterizing bacterial protein synthesis inhibitors”. Antimicrobial Agents and Chemotherapy, 57(12), 5994-6002.

[17] FDA. (2023). Antibacterial Therapies: Ribosomal Inhibitors. U.S. Food and Drug Administration. https://www.fda.gov/drugs/antibacterial-therapies (Accessed: 2025).

[18] World Health Organization. (2024). Antimicrobial resistance: global report on surveillance. Geneva: WHO Press. https://www.who.int/publications/amr-report-2024 (Accessed: 2025).

[19] CDC. (2022). Diphtheria Toxin: Mechanism and Clinical Implications. Centers for Disease Control and Prevention. https://www.cdc.gov/diphtheria/toxin-mechanism.html (Accessed: 2025).

[20] NCBI Bookshelf. (2021). Ribosome-Inactivating Proteins: Shiga and Shiga-like Toxins. National Center for Biotechnology Information. https://www.ncbi.nlm.nih.gov/books/NBK563215/ (Accessed: 2025).

Downloads

Published

2026-05-10